991-P: High Treatment Satisfaction with 3-Day Insulin Patch Is Independent of Patient Demographics
| Autor: | Robert Rook, Jay L. Warner, Buddug R. Rees, Don Johns, Brian L. Levy, Mark Peyrot |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Diabetes. 69 |
| ISSN: | 1939-327X 0012-1797 |
| Popis: | This post-hoc analysis explores whether high treatment satisfaction seen with a 3-day wearable patch for mealtime insulin subcutaneous delivery is applicable across different patient groups. The randomized multi-country study of adults (n=278, age: 59.2±8.9 years) with type 2 diabetes transitioned patients from basal-only to basal plus mealtime insulin therapy using one of two methods of mealtime insulin delivery. Patients were randomized 1:1 to deliver mealtime insulin using either a 3-day insulin patch or an insulin pen. Published data demonstrated that basal plus mealtime insulin therapy using either device similarly reduced A1C (1.7% patch, 1.6% pen). However, patients were more satisfied with patch than pen (Overall Satisfaction, Insulin Delivery System Rating Questionnaire (IDSRQ) p In summary, the data indicate that the 3-day insulin patch is suitable for patients independent of demographics, and preferred to pen overall. Disclosure M. Peyrot: Advisory Panel; Self; Eli Lilly and Company. Consultant; Self; CeQur Corporation, Eli Lilly and Company. Research Support; Spouse/Partner; Eli Lilly and Company. D. Johns: None. B.R. Rees: Employee; Self; CeQur Corporation. R. Rook: Consultant; Self; CeQur Corporation. J.L. Warner: Employee; Self; CeQur Corporation. B.L. Levy: Consultant; Self; CeQur Corporation, Digma Medical, iGlucose, LifeScan, Inc., QuiO Technologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|